<DOC>
	<DOCNO>NCT02565862</DOCNO>
	<brief_summary>This study aim provide clinical information potential drug-drug interaction daclatasvir metformin .</brief_summary>
	<brief_title>A Drug-drug Interaction Study Between Daclatasvir Metformin</brief_title>
	<detailed_description>Daclatasvir recently approve anti-HCV agent cytochrome P450 3a ( CYP3A ) substrate affect CYP3A . It also moderate inhibitor various membrane transporter organic anion-transporting polypeptide 1B1 ( OATP1B1 ) , p-glycoprotein ( P-gP ) , organic cation transporter ( OCT ) 1 2 . Metformin use treat diabetes mellitus . It OCT-2 OCT-1 substrate combine daclatasvir increase level metformin may occur , risk hypoglycaemic episode . The Summary Product Characteristics ( SmPC ) daclatasvir currently mention potential drug-drug interaction . HCV associate insulin resistance ( IR ) may develop diabetes mellitus ( DM ) . The prevalence IR HCV infect patient estimate vary 30 % 70 % . Several study show IR negative impact achievement undetectable HCV viral load complete 12 week treatment ( Sustained Virologic Response ( SVR ) ) . This study aim provide clinical information potential drug-drug interaction daclatasvir metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Subject least 18 old 55 year screen . 2 . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior Day 1 . 3 . Subject Quetelet Index ( Body Mass Index ) 18 35 kg/m2 , extremes include . 4 . Subject able willing sign Informed Consent Form prior screen evaluation . 5 . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior Day 1 . Results biochemistry , haematology urinalysis test within laboratory 's reference range ( see Appendix A ) . If laboratory result within reference range , subject include condition Investigator judge deviation clinically relevant . This clearly record . 6 . Subject normal blood pressure pulse rate , accord Investigator 's judgement . 1 . Creatinine clearance 60mililiter/minute ( ml/min ) . 2 . Documented history sensitivity/idiosyncrasy medicinal product excipients . 3 . Positive HIV test . 4 . Positive hepatitis B C test . 5 . Pregnant female ( confirm Human chorionic gonadotropin ( hCG ) test perform less 4 week day 1 ) breastfeed female . Female subject childbearing potential without adequate contraception , e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , two year postmenopausal . They must agree take precaution order prevent pregnancy throughout entire conduct study . 6 . Therapy drug ( two week precede Day 1 ) , except acetaminophen ( max 2 gram/day ) . 7 . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , psychiatric disorder , gastrointestinal disorder , renal hepatic disorder ( increase alanine aminotransferase ( ALAT ) /ASAT ) , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . 8 . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . 9 . History current abuse drug , alcohol solvent . 10 . Inability understand nature extent study procedure require . 11 . Participation drug study within 60 day prior Day 1 . 12 . Donation blood within 60 day prior Day 1 . 13 . Febrile illness within 3 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HCV</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Metformin</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>